Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Extranodal NK/T-cell lymphoma, drawn from the whole corpus: 7 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
The disease is common in east Asia and Latin America and rare in the countries that run most randomised trials, so the regimens that work best were developed where most of the patients are and are least familiar where the rest of them are treated.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Randomised comparisons between the asparaginase-containing regimens are few. A 42-patient trial in newly diagnosed advanced disease favoured DDGP over SMILE, and the 256-patient NHL-004 phase 3 trial in early-stage nasal disease found no significant difference in five-year survival between two pegaspargase regimens given with radiotherapy. Most of the regimens in use have never been compared with each other, and they differ substantially in toxicity.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
PD-1 and PD-L1 blockade produce responses in relapsed disease, and the evidence is single-arm studies. Randomised trials of adding these drugs to first treatment are registered on ClinicalTrials.gov, among them NCT04365036 with toripalimab in early-stage disease, and none had reported when the registry was read on 17 November 2026.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
The commonest clinical failure is delay: the presentation looks like sinusitis, and the biopsy is often taken months after the symptoms began.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
The presentation looks like sinusitis: blockage, bleeding, crusting and pain in the nose, often treated with antibiotics and steroids for months. A biopsy taken through the nose is often necrotic and non-diagnostic, so repeat biopsies are common and are not a failure. The diagnosis needs in situ hybridisation for Epstein-Barr-encoded RNA, which is positive in every tumour cell by definition, together with an NK-cell phenotype: CD56 positive, surface CD3 negative with cytoplasmic CD3-epsilon positive, and cytotoxic granule proteins present. A gut lesion with the same markers but no virus is the indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract, which regresses on its own; WHO-HAEM5 says it is most important not to mistake one for the other.
Progression-free survival hazard ratio 0.
WHO-HAEM5 renamed the entity extranodal NK/T-cell lymphoma, recognising its presentation at several extranodal sites; the International Consensus Classification kept the nasal type qualifier.
Objective response in 21 of 28 (75.
PET-CT of the whole body, magnetic resonance imaging of the face and sinuses to map local destruction, examination of the nose and throat, and a measurement of Epstein-Barr virus DNA in the blood, which tracks the disease and is an independent predictor of survival. The index in use is PINK, built from 527 patients treated without anthracyclines at 38 hospitals in 11 countries, which counts age over 60, stage III or IV, involvement of distant lymph nodes, and disease starting outside the nose: three-year overall survival was 81 per cent with none of those, 62 per cent with one and 25 per cent with two or more. Adding the viral DNA level gives a second version, PINK-E.